Clinical Trial Investigating the Effects of EP395 Following an Inhaled Endotoxin Challenge in Healthy Adults

Phase 1 Completed 40 enrolled EpiEndo Pharmaceuticals FGK Clinical Research GmbH · collab

RandomizedParallel-groupDouble-blindOther

Summary

The aim of this clinical trial is to assess the effect of EP395 in a model of lung inflammation (inhaled lipopolysaccharide, which causes temporary inflammation in the airways). In addition, further information on the safety and tolerability of EP395 will be collected.

Timeline

Start: 2025-02-20
Primary completion: 2025-08-25
Completion: 2025-08-25

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	glasmacinal	Small molecule	—	Oral

Indications

No indication recorded.